ARTICLE | Company News
Cleveland BioLabs, U.S. Department of Defense other news
July 11, 2011 7:00 AM UTC
Cleveland BioLabs received an additional $1.5 million from the DoD to develop CBLB502 to treat acute radiation syndrome (ARS), bringing the total contract to up to $46.2 million, which includes an option for DoD to purchase up to $30 million worth of CBLB502 if the radioprotectant derivative of flagellin is approved by FDA. Cleveland BioLabs initially received $14.8 million from the DoD in September (see BioCentury, Sept. 27, 2010). ...